Baseline characteristics of Metastatic Melanoma Patients receiving Immune Checkpoint Inhibitors
| Normal Weight | Overweight | Obesity | Pvalue | ||
|---|---|---|---|---|---|
| N(%) | Total = 423 | 139 (33) | 165 (39) | 119 (28) | |
| Age (mean(SD)) | 62.1(16) | 64.5(14) | 66(13) | 0.09 | |
| Gender | Male | 75(54) | 114(69) | 78(66) | 0.02 |
| Female | 64(46) | 51(31) | 41(34) | ||
| Stage | Stage III | 11(8) | 14(8) | 15(13) | 0.38 |
| Stage IV | 128(92) | 151(92) | 104(87) | ||
| ICI Treatment | CTLA-4 | 64(46) | 75(45) | 61(51) | 0.65 |
| PD-1 | 49(35) | 55(33) | 41(34) | ||
| Combination | 26(19) | 35(21) | 17(14) | ||
| ECOG Performance Status | 0 | 93(69) | 120(75) | 90(80) | 0.18 |
| >=1 | 41(31) | 40(25) | 23(20) | ||
| LDH | Normal | 71(62) | 97(69) | 73(79) | 0.02 |
| High | 44(38) | 44(31) | 19(21) | ||
| BRAF Mutation | V600 | 7(8) | 9(8) | 10(12) | 0.06 |
| Other | 0(0) | 5(4) | 0(0) | ||
| WT | 84(92) | 101(88) | 74(88) | ||
| Number of metastatic sites [mean (SD)] | 2.6(1) | 2.7(1) | 2.3(1) | 0.05 | |
| Line of TRT | First Line | 87(63) | 108(65) | 77(65) | 0.87 |
| Non-First Line | 52(37) | 57(35) | 42(35) | ||
| Alive Status | Alive | 71(51) | 77(47) | 59(50) | 0.74 |
| Dead | 68(49) | 88(53) | 60(50) | ||
| Follow up months [median (range)] | 33.1(1.4-121.1) | 38.6(2.7-172.2) | 37.7(11.0-173.3) | 0.52 | |